Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.

Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS.

Transl Res. 2011 May;157(5):265-72. doi: 10.1016/j.trsl.2011.01.005.

2.

Hypertrophy-associated polymorphisms ascertained in a founder cohort applied to heart failure risk and mortality.

Parsa A, Chang YP, Kelly RJ, Corretti MC, Ryan KA, Robinson SW, Gottlieb SS, Kardia SL, Shuldiner AR, Liggett SB.

Clin Transl Sci. 2011 Feb;4(1):17-23. doi: 10.1111/j.1752-8062.2010.00251.x.

3.

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J; Gynecological Cancer Intergroup..

Int J Gynecol Cancer. 2011 Feb;21(2):419-23. doi: 10.1097/IGC.0b013e3182070f17.

PMID:
21270624
4.

MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes.

Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR.

Genet Epidemiol. 2010 Dec;34(8):816-34. doi: 10.1002/gepi.20533.

5.

A map of human genome variation from population-scale sequencing.

1000 Genomes Project Consortium., Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA.

Nature. 2010 Oct 28;467(7319):1061-73. doi: 10.1038/nature09534. Erratum in: Nature. 2011 May 26;473(7348):544. Xue, Yali [added]; Cartwright, Reed A [added]; Altshuler, David L [corrected to Altshuler, David]; Kebbel, Andrew [corrected to Keebler, Jonathan]; Koko-Gonzales, Paula [corrected to Kokko-Gonzales, Paula]; Nickerson, Debbie A [corrected to Nickerson, Deborah A].

6.

Common variants at 19p13 are associated with susceptibility to ovarian cancer.

Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; Australian Ovarian Cancer Study Group.; Australian Cancer Study (Ovarian Cancer).; Ovarian Cancer Association Consortium., Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA.

Nat Genet. 2010 Oct;42(10):880-4. doi: 10.1038/ng.666. Erratum in: Nat Genet. 2016 Jan;48(1):101. Brook-Wilson, Angela [corrected to Brooks-Wilson, Angela].

7.

Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain.

Kao WT, Wang Y, Kleinman JE, Lipska BK, Hyde TM, Weinberger DR, Law AJ.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15619-24. doi: 10.1073/pnas.1005410107.

8.

LocusZoom: regional visualization of genome-wide association scan results.

Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ.

Bioinformatics. 2010 Sep 15;26(18):2336-7. doi: 10.1093/bioinformatics/btq419.

9.

Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci.

Gamazon ER, Huang RS, Cox NJ, Dolan ME.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):9287-92. doi: 10.1073/pnas.1001827107.

10.

Pharmacogenomic discovery using cell-based models.

Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME.

Pharmacol Rev. 2009 Dec;61(4):413-29. doi: 10.1124/pr.109.001461. Review.

11.

The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Brown PO, Palmer C.

PLoS Med. 2009 Jul;6(7):e1000114. doi: 10.1371/journal.pmed.1000114.

12.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006.

13.

ALDH1 expression correlates with favorable prognosis in ovarian cancers.

Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J.

Mod Pathol. 2009 Jun;22(6):817-23. doi: 10.1038/modpathol.2009.35.

14.

Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.

Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-Trench G, Pearce CL, Hogdall E, Whittemore AS, McGuire V, Hogdall C, Blaakaer J, Wu AH, Van Den Berg DJ, Stram DO, Menon U, Gentry-Maharaj A, Jacobs IJ, Webb PM, Beesley J, Chen X; Australian Cancer (Ovarian) Study.; Australian Ovarian Cancer Study Group., Rossing MA, Doherty JA, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, Thompson PJ, Carney ME, Ness RB, Moysich K, Goode EL, Vierkant RA, Cunningham JM, Anderson S, Schildkraut JM, Berchuck A, Iversen ES, Moorman PG, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Anton-Culver H, Ziogas A, Brewster WR, Ponder BA, Easton DF, Gayther SA, Pharoah PD; Ovarian Cancer Association Consortium (OCAC)..

Hum Mol Genet. 2009 Jun 15;18(12):2297-304. doi: 10.1093/hmg/ddp138.

15.

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P.

PLoS Genet. 2009 Mar;5(3):e1000433. doi: 10.1371/journal.pgen.1000433.

16.

New-generation platinum agents for solid tumors.

Shah N, Dizon DS.

Future Oncol. 2009 Feb;5(1):33-42. doi: 10.2217/14796694.5.1.33. Review.

PMID:
19243296
17.

Survival-related profile, pathways, and transcription factors in ovarian cancer.

Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, van der Zee AG.

PLoS Med. 2009 Feb 3;6(2):e24. doi: 10.1371/journal.pmed.1000024.

18.

Does parental expressed emotion moderate genetic effects in ADHD? An exploration using a genome wide association scan.

Sonuga-Barke EJ, Lasky-Su J, Neale BM, Oades R, Chen W, Franke B, Buitelaar J, Banaschewski T, Ebstein R, Gill M, Anney R, Miranda A, Mulas F, Roeyers H, Rothenberger A, Sergeant J, Steinhausen HC, Thompson M, Asherson P, Faraone SV.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1359-68. doi: 10.1002/ajmg.b.30860.

PMID:
18846501
19.

Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans.

Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME.

Mol Cancer Ther. 2008 Sep;7(9):3038-46. doi: 10.1158/1535-7163.MCT-08-0248.

20.

ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.

Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H; AOCS Study Group., Harnett PR, Brown R, DeFazio A, Chenevix-Trench G.

Clin Cancer Res. 2008 Sep 1;14(17):5594-601. doi: 10.1158/1078-0432.CCR-08-0606. Erratum in: Clin Cancer Res. 2012 Jan 1;18(1):319-20.

Items per page

Supplemental Content

Support Center